ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 511-521

  Jensen, Jeanette Dupont ^a,b   Knoop, Ann ^a,b   Ewertz, Marianne ^a,b   Laenkholm, Anne Vibeke ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c University Hospital of Copenhagen ^*  (Denmark)

Author keywords

Breast cancer; ER; HER2; Metastases; Primary tumor; Synchronous axillary nodes; TOP2A

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISTANT METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SKIN METASTASIS;

ANTIGENS, NEOPLASM; BIOPSY; BREAST NEOPLASMS; CARCINOMA; DENMARK; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859103835     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1610-3     Document Type: Article

References (57)

1. Amir E, Clemons M (2009) Should abiopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10:933-935
2. Broom RJ, Tang PA, Simmons C et al (2009) Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29:1557-1562
3. Locatelli MA, Curigliano G, Fumagalli L, et al (2010) Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol (Meeting Abstracts) 28:CRA1008
4. Lindstrom LS, Karlsson E, Wilking U, Bergh J (2010) Discordance in Hormone Receptor and HER2 status in breast cancer during tumor progression. SABCS Meeting Abstracts S3-5
5. Amir E, Clemons M, Freedman OC, et al (2010) Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol (Meeting Abstracts) 28:1007
6. Gutierrez MC, Detre S, Johnston S et al (2005) Molecular changes intamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476 (Pubitemid 47050837)
7. Johnston SRD, Saccani-Jotti G, Smith IE et al (1995) Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331-3338
8. Simmons C, Miller N, Geddie W et al (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499-1504
9. Guarneri V, Giovannelli S, Ficarra G et al (2008) Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 13:838-844
10. Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953-1958
11. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14:2584-2589 (Pubitemid 26300127)
12. Li BD, Byskosh A, Molteni A, Duda RB (1994) Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71-77 (Pubitemid 24299653)
13. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552-556 (Pubitemid 43079998)
14. Edgerton SM, Moore II D, Merkel D, Thor AD (2003) erbB-2 (HER-2) and breast cancer progression (Miscellaneous Article). Appl Immunohistochem Mol Morphol 11:214-221 (Pubitemid 37082057)
15. Lower EE, Glass E, Blau R, Harman S (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301-306
16. Wilking U, Karlsson E, Skoog L et al (2011) HER2 status in apopulation-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 125:553-561
17. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase II{alpha} in primary and metastatic breast cancer. Cancer Res 61:5345-5348 (Pubitemid 32694907)
18. Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036-1043
19. Gong Y, Booser DJ, Sneige N (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103:1763-1769 (Pubitemid 40563246)
20. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30:259-265 (Pubitemid 30620800)
21. Ejlertsen B, Jensen MB, Nielsen KV et al (2010) HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 28:984-990
22. Knoop AS, Knudsen H, Balslev E et al (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490 (Pubitemid 46291811)
23. Nielsen KV, Ejlertsen B, Moller S, et al (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 47:725-734 (Pubitemid 351878451)
24. Press MF, Sauter G, Buyse M, et al (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859-867
25. Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388
26. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20:1319-1329
27. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
28. Hilton JF, Amir E, Hopkins S, et al (2010) Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1264-6
29. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918-926 (Pubitemid 39089280)
30. Carlsson J, Nordgren H, Sjostrom J et al (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90:2344-2348 (Pubitemid 38961898)
31. D'Andrea MR, Limiti MR, Bari M et al (2007) Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 101:279-284 (Pubitemid 46169881)
32. Cardoso F, Leo AD, Larsimont D et al (2001) Evaluation of HER2, p53, bcl-2, topoisomerase II-+: heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12:615-620 (Pubitemid 32519912)
33. Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in abasal-like breast cancer metastasis and xenograft. Nature 464: 999-1005
34. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol 9:M57-M60
35. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150 (Pubitemid 29416439)
36. MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. Proceedings of ASCO 2008; Abstr 1000
37. Mittendorf EA, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381-7388
38. Hurley J, Doliny P, Reis I et al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24:1831-1838
39. Burstein HJ, Harris LN, Gelman R et al (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46-53
40. Harris LN, You F, Schnitt SJ et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207 (Pubitemid 46424061)
41. Heim S, Teixeira MR, Dietrich CU, Pandis N (1997) Cytogenetic polyclonality intumors of the breast. Cancer Genet Cytogenet 95:16-19
42. Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678-682
43. Vance GH, Barry TS, Bloom KJ et al (2009) Genetic heterogeneity inHER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133:611-612
44. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, Cohen C (2010) Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol
45. Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805:105-117
46. Teixeira MR, Pandis N, Bardi G, Andersen JA, Mitelman F, Heim S (1995) Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int J Cancer 63:63-68
47. Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR (2007) Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat 102:143-155 (Pubitemid 46452166)
48. Symmans WF, Liu J, Knowles DM, Inghirami G (1995) Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 26:210-216
49. Kuukasjarvi T, Karhu R, Tanner M et al (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597-1604 (Pubitemid 27175581)
50. Stoecklein NH, Klein CA (2010) Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 126:589-598
51. Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302-312
52. Bussolati G, Leonardo E (2008) Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61:1184-1192
53. Boenisch T (2005) Effect of heat-induced antigen retrieval following inconsistent formalin fixation. Appl Immunohistochem Mol Morphol 13:283-286
54. Gancberg D, di LA, Rouas G et al (2002) Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol 55:315-317
55. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 0 AD;80:1943-1949
56. Graham AD, Faratian D, Rae F, Thomas JJ (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52:847-855 (Pubitemid 351724917)
57. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT (2007) Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60:397-404 (Pubitemid 46596559)